Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thor Medical ASAFRA:8NN -1.89%27 Debt-to-EBITDA is -4.42 as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 305 Biotechnology companies, Thor Medical ASA ranks worse than 327868.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Thor Medical ASA's Debt-to-EBITDA or its related term are showing as below:
FRA:8NN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.21 Med: -0.02 Max: 0.01
Current: -4.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of Thor Medical ASA was 0.01. The lowest was -4.21. And the median was -0.02.
FRA:8NN's Debt-to-EBITDA is ranked worse than 100% of 305
companies
in the Biotechnology industry
Industry Median: 1.33
vs FRA:8NN: -4.20
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Thor Medical ASA Debt-to-EBITDA Related Terms
Thor Medical ASA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8NN vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Thor Medical ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Thor Medical ASA (FRA:8NN) has a Debt-to-EBITDA of -4.42 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thor Medical ASA. According to the industry distribution chart, Thor Medical ASA ranks #999999 out of 305 companies in the Biotechnology industry.
Is Thor Medical ASA's Debt-to-EBITDA too high?
Thor Medical ASA's current Debt-to-EBITDA is -4.42. Based on the distribution chart, Thor Medical ASA ranks #999999 out of 305 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Thor Medical ASA has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #999999 out of 305 companies for Debt-to-EBITDA. This places Thor Medical ASA in the lower half of its industry. The industry median Debt-to-EBITDA is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.33, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thor Medical ASA. For the Biotechnology industry, the median Debt-to-EBITDA is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thor Medical ASA's current Debt-to-EBITDA is -4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Debt-to-EBITDA of -4.42. The current Debt-to-EBITDA is -4.42. Thor Medical ASA's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Debt-to-EBITDA is -4.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
27GF Score
Get the complete analysis for FRA:8NN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
